ESMO 2024 Summary: Management of Oligoprogressive Disease - Patients…

2024 ESMO Annual Meeting Insights Hub

R. Van den Begin

ESMO 2024 Summary: Highlights of Important Trials in Sarcoma

2024 ESMO Annual Meeting Insights Hub

R. Jones

Developmental Therapeutics Highlights From ASCO® 2024

2024 ASCO® Annual Meeting Insights Hub

G. Sonpavde

ASCO® 2024 Highlights: Advances in GIST Tumors and Soft Tissue Sarco…

2024 ASCO® Annual Meeting Insights Hub

A. Hussein

2024 Update in Sarcomas

Total Health

D. Portnoy

Sarcoma 101: Multidisciplinary Approach, Therapies, and Future Direc…

Total Health

B. Wilky

ASCO® 2024 Highlights in Sarcomas

2024 ASCO® Annual Meeting Insights Hub

R. Jones

Afami-Cel TCR for Sarcoma

Moffitt Cancer Center

B. Van Tine

Sarcoma Insights: Types, Diagnosis, and Treatment Approaches

Total Health

M. Orians, D. Portnoy

NCCN Clinical Practice Guidelines for Treating GIST

Andrea Napolitano

Year in Review 2024 - Transformative FDA Approvals in Precision Onco…

Oncology 2024 Year in Review

V. Subbiah

Precision Oncology in the Diagnosis and Management of Sarcoma

University of Miami Sylvester Comprehensive Cancer Center

S. Bialick

Gastrointestinal Stromal Tumors (GIST) and Resistance Mutations

Warren Chow

Divide and Conquer Sarcomas Through Precision Oncology

Miami Cancer Institute Precision Oncology Symposium

N. Somaiah

Sarcoma Panel Discussion: Molecular Tumor Board - Multidisciplinary …

University of Miami Sylvester Comprehensive Cancer Center

P. Seo, A. Rosenberg, P. Castillo, M. De La Fuente, S. Gultekin, E. Krill-Jackson, C. Gomez

Systemic Therapies for Uterine Leiomyosarcoma

OncoAlert

I. Ray-Coquard

ERS 2023 Insights: Novel Methods of Symptom Monitoring and Managemen…

ERS 2023 Insights

K. Ilene Aronson

What Is New in Treatment of Soft Tissue and Bone Sarcoma

ISCO - International School of Clinical Oncology

S. Stacchiotti

ASCO® 2024 Insights: "PROs of the MEDISARC Study (AIO-STS-0415) - Du…

2024 ASCO® Annual Meeting Insights Hub

V. Grünwald

ctDNA Analysis From INTRIGUE Study: Updated OS & Safety With Ripreti…

Insights from 2024 ESMO Sarcoma and Rare Cancers Congress

J. Blay